Towards systemic reform beyond prohibition — IDPC submission to the CND independent expert panel on drugs

Publications

Towards systemic reform beyond prohibition — IDPC submission to the CND independent expert panel on drugs

17 November 2026

IDPC is a global network representing 207 NGOs across 75 countries. Our vision is drug policies that advance social justice and human rights. We welcome this opportunity to make a written submission to the CND Expert Panel.

The resolution-mandated task of the Panel is to consider implementation of the drug control conventions, but also of other relevant international instruments and all international drug policy commitments. The Panel must therefore acknowledge the universal, primary and inalienable nature of human rights.

The evidence is indisputable: punitive drug control does not sustainably deter drug use or supply, but fuels systematic human rights violations and – as UNODC outlined in 2008 – creates harmful unintended consequences. In particular, countries across the Global South have been disproportionately harmed by the war on drugs, related violence and armed conflicts, forced eradication, and existential threats to democracy. Yet the drug control machinery remains deeply resistant to change – a stubbornness rooted in the architecture of the system itself. The Panel must acknowledge the failures and harms of prohibition in order to meaningfully shape the way forward.

The Panel has a historic opportunity to promote approaches that truly protect the welfare of humankind. It should focus on areas where existing implementation falls short, as well as where the system itself creates barriers. Crucially, limiting to reforms within the existing drug conventions will be insufficient, and bold recommendations are needed that challenge the premise of prohibition itself.

1. Where treaty implementation and guidance fall short

Effective policies that are permitted – explicitly or within the purported ‘flexibility’ of the conventions – are lacking in clear support, guidance, advocacy, funding and endorsement from UNODC, INCB and CND, and their implementation remains uneven and insufficient.

For example, the decriminalisation of drug use and personal possession is permissible within the treaties and widely endorsed by the UN human rights system, UNAIDS and other UN partners. All three drug conventions include specific clauses permitting the provision of “alternative[s] to conviction or punishment”. The 1988 treaty requirement to establish personal possession of drugs as a criminal offence comes with sufficient disclaimers relating to a nation’s constitutional and legal principles, and does not specify the responses to be implemented. So why are more than two million people every year still being prosecuted for these low-level offences?

The ongoing criminalisation of people who use drugs deters access to health and social services, and fuels mass incarceration and prison overcrowding. Full decriminalisation should be the norm rather than the exception, yet leadership and guidance from UNODC has been incredibly weak. Today, only around 30 countries have adopted some form of decriminalisation.

Harm reduction services are the most intensely researched approach available to Member States. A suite of contemporary UN resolutions, declarations and instruments provide clear support for this approach. But, again, leadership and guidance from UNODC remains weak and is inconsistent with other UN agencies – meaning that progress and developments on harm reduction come from outside of, and in spite of, the UN drug control machinery. Rather than being sidelined as a ‘politically controversial’ issue, the inclusion of community-led harm reduction as part of a balanced drug policy should be framed as an essential component of the right to health – with failure to do so being considered a treaty violation.

Recommendations

  • Clearly establish the legality of harm reduction, full decriminalisation and other non-punitive responses in accordance with the drug control treaties, but also their necessity as an integral part of a human rights-based response.
  • Urge UNODC to provide better, more coherent technical assistance and guidance on the implementation of harm reduction and decriminalisation – with robust monitoring mechanisms to ensure that these approaches increasingly become standard practice.
  • Outline areas that require further research and exploration to feed into the drafting of the 2029 Political Declaration and high-level review – such as existing implementation gaps and emerging responses for people who use stimulant drugs.

2. Beyond treaty implementation – the limits of the current framework

One ‘structural sin’ of the treaties is the establishment of a ‘floor’ but no ‘ceiling’: establishing minimum requirements and measures such as the criminalisation of various activities, but placing no limits on the maximum penalties that can be applied. This directly results in extreme responses such as the death penalty, extrajudicial killings, militarised attacks, arbitrary detention, etc – all violations of human rights justified in the name of drug control. Appeals for greater proportionality and better implementation are insufficient: such egregious and harmful practices can only be curtailed by the addition of a rights-based ‘ceiling’ within the treaties themselves.

A growing number of countries are also adopting the legal regulation of controlled substances. For the Panel, regulated markets cannot be downplayed as a taboo abstract: an estimated 380 million people already live in jurisdictions that have established either commercial or government-controlled systems for the production, supply and sale of cannabis. Again, progress in this area comes from outside of, and in spite of, the UN drug control system – with opportunities missed to better shape, study and align approaches, to promote the inclusion of traditional growers, and to mitigate risks of corporate capture.

Responsible regulation clearly demonstrates the ‘Limits of Latitude’ within the treaties, but has the potential to better protect human rights by reducing exposure to harmful substances, taking profits away from criminal groups, reducing violence, and facilitating access to health and social services. This solution requires treaty revision and reform, rather than better implementation of existing flexibilities.

Recommendations

  • Explore the mechanisms, including treaty reform and/or new protocols, to impose a ‘ceiling’ that prevents the use of extreme measures that violate human rights in the name of drug control.
  • Acknowledge that only treaty review and reform can bring legally regulated markets in line with the drug treaties. If there is disagreement within the Panel on how best to proceed, recommend new UN-wide normative guidance based on independent, unbiased and scientific analysis of legal regulation models and their impacts on health, rights, security and development.
  • Recommend that concrete legal avenues are explored, including inter se agreements, for Member States wanting to pursue legal regulation without contravening international law – and that the UN system provides coherent guidance on this approach.

3. Weak links in the machinery

The 2018 UN Common Position on drugs was a major development, and created a UN Task Team to oversee implementation. Yet a lack of leadership from UNODC has left the Task Team moribund and falling short of its purpose to unify UN voices and better support Member States. In 2019, OHCHR, WHO, UNAIDS and UNDP endorsed the International Guidelines on Human Rights and Drug Policy to support governments with implementing treaty obligations. UNODC has not endorsed, co-badged or used these Guidelines.

Indeed, the Panel should conduct an honest assessment of whether UNODC, INCB and the CND have become part of the problem, rather than part of the solution. Originally conceived as a coordination platform and catalyst for UN system-wide efforts, UNODC is silent or hostile on key issues such as harm reduction, decriminalisation and responsible regulation – and on human rights more broadly. The Panel should explore the political and financial factors that impede UNODC’s coherence with the rest of the UN system: including an over-reliance on earmarked funding, long-term shortcomings of senior leadership, and the highly politicised nature of CND (its governing body).

Outside of Vienna, the WHO’s Expert Committee on Drug Dependence (ECDD) also warrants the Panel’s urgent attention. The ECDD is critical to the drug control machinery, and it must be funded and empowered accordingly. However, recent reviews of cannabis and the coca leaf have highlighted shortcomings of the ECDD when its scope is limited to medical, scientific, chemical and pharmacological findings at the expense of significant social, economic, accessibility, cultural, traditional medicine and human rights considerations. For example, the coca leaf review saw centuries of Indigenous knowledge overlooked.

The ECDD relies on earmarked (not core) funding, impeding its work and independence. Membership of the ECDD has also moved away from a more robust public health approach, with a disproportionate focus on pharmacology in the absence of more robust and diverse selection criteria in Guidelines that have not been updated since 2010.

Recommendations

  • The UN Task Team should be reinvigorated as a joint UN-wide programme on drugs – rehoused under the auspices of the UN Secretary-General, and resourced to deliver on ambitious work plans and activities, including actioning Panel recommendations.
  • UNODC must officially endorse, support and use the International Guidelines on Human Rights and Drug Policy.
  • The mandates of UNODC, INCB and CND must be updated to explicitly include human rights obligations in their scope of work.
  • Every UNODC project and activity, including those funded by earmarked contributions, must be subjected to transparent and comprehensive human rights impact assessments conducted alongside OHCHR.
  • WHO should update the 2010 Guidance on substance reviews to learn from deficiencies in the cannabis and coca leaf review processes, strengthening a public health approach and the consideration of human rights, traditional medicines and Indigenous knowledge.
  • The ECDD must be funded by core budgets, to ensure that its work is truly independent.